ME: 23andMe Inc. Market Cap to Revenue Ratio

Brandmark of 23andMe Holding Co (ME)

The crisis and the layoffs of leading geneticists call the survival of 23andMe Holding Co. (ME) into question. Historical P/S dynamics reflect market expectations, where the current value of the metric stands at 0.10. Meanwhile, 23andMe Holding Co. (ME) relies on robotic automation of DNA tests and possesses a colossal biodata database, creating a foundation for the development of innovative drugs and future therapies.

ME 23andMe Inc.: P/S Multiple in the range 07/04/2022 - 04/05/2025

Analytical breakdowns for 23andMe Holding Co. (ME)

- stock price and consensus target price:
Share Price 23andMe|ME - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization 23andMe|ME - Total Company Value
- business book valuation details:
Accounting Value per Share 23andMe|ME - Book Capitalization|Market-to-Book Ratio 23andme.com|ME - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio 23andMe Holding Co.|ME - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital 23andme.com|ME - Company Debts|Debts to Book Value 23andMe|ME - Company Long-Term Debt|Company Short-Term Debt 23andMe|Immediate Liquidity Ratio 23andme.com
- business earnings and investment ratios data:
ME - Net Profit|Company Profit Forecast 23andMe Holding Co.|ME - Price to Earnings Ratio|Price to Future Earnings Ratio 23andMe Inc.|ME - PEG Multiple|Enterprise Value to EBITDA Multiple 23andMe Holding Co.|ME - Operating profit before deduction of amortization|Earnings per share for the trailing year 23andMe|ME - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months 23andme.com|ME - Earnings per share growth in current year|Expected net earnings per share growth next year 23andMe Holding Co.
- issuer revenue and sales details:
ME - Company Sales|Company Future Sales 23andMe Holding Co|ME - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple 23andMe Inc
Fundamental company analysis:ME - 23andMe Holding Co
Finished products of 23andMe Inc

The assessment of the asset's operational efficiency is based on the company's market capitalization to revenue ratio, allowing investors to determine the premium paid per unit of sales. By analyzing changes in the P/S multiple, one can evaluate the resilience of 23andMe Holding Co. (ME) amid stringent US data privacy regulations, where the encapsulation of databases determines the business's real value and the risk of capital stagnation.

Competitors of 23andMe Holding Co.

Price-to-Revenue Ratio A (Agilent)|P/S Multiple DGX (questdiagnostics.com)|Illumina Platform - Price-to-Revenue Ratio|Exact Sciences Inc. - P/S Multiple|RVTY: Price-to-Revenue Ratio|Bio-Rad (BIO) - Price-to-Revenue Ratio|NNNN - Price-to-Revenue Coefficient|SHC (Sotera Health Corp) - P/S Multiple|Price to Sales QuidelOrtho Inc. QDEL|P/S Multiple OPK|CareDx - Market Cap to Revenue Ratio|P/S Multiple MRVI (Maravai LifeSciences Holdings)|Market Cap to Sales Volume FLGT (Fulgent Corp)|LAB: Market Cap to Revenue|Price-to-Revenue Coefficient Cytek Corp CTKB|OSUR (OraSure Technologies Inc) - Market Cap to Revenue|Market Cap to Revenue Exagen Inc.|Market Cap to Revenue MDXH|LUCD - Price-to-Revenue Multiple|Price-to-Revenue Ratio Prenetics (PRE)|Price-to-Revenue Ratio IMDX (Insight Molecular Diagnostics Inc)|Trinity Biotech - Market Cap to Revenue|prophaselabs.com - Price-to-Revenue Ratio|AIMD - Price-to-Revenue Ratio|Co-Diagnostics Inc (CODX) - Market Cap to Revenue|HSCS: P/S Multiple|BMRA - Price-to-Revenue Coefficient|Market Cap to Revenue CDIO|Price to Sales onconetix.gcs-web.com ONCO|Price-to-Revenue Ratio Virax Biolabs (VRAX)|Market Cap to Sales Volume BJDX|Price-to-Revenue Ratio Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Price to Sales|centogene.com - P/S Multiple|ENZ (Enzo Biochem Inc.) - Market Cap to Revenue Ratio|Price to Sales FRES|Price to Sales GTG Labs (GENE)|PMD (Psychemedics Corp.) - P/S Multiple